Cyclodextrin-in-Liposome for therapy: Advances and challenges.

Area of Science:

• Nanotechnology
• Pharmaceutical Sciences
• Drug Delivery Systems

Background:

• Cyclodextrins (CDs) are effective solubilizers but have poor oral bioavailability and rapid dissociation.
• Liposomes can encapsulate hydrophobic drugs but face challenges with membrane stability and low loading rates.
• Drug-in-cyclodextrin-in-liposomes (DCLs) were introduced to combine the benefits of CDs and liposomes.

Purpose of the Study:

• To review the advantages of CD-in-liposomes (CLs) as drug delivery carriers.
• To explore the potential of CLs and DCLs in transporting free CDs or CD/drug complexes.
• To summarize literature on CL- and DCL-based formulations for disease treatment and their mechanisms.

Main Methods:

• Literature review of scientific publications on CLs and DCLs.
• Analysis of advancements in cyclodextrin and liposome technologies.
• Examination of drug loading, stability, targeting, and in vivo distribution mechanisms.

Main Results:

• CLs offer improved bioavailability and controlled release compared to standalone CDs.
• Liposomes enable surface modification for targeted delivery, a challenge for CDs alone.
• CLs and DCLs show promise in treating various diseases by enhancing drug efficacy and reducing side effects.

Conclusions:

• CD-in-liposomes represent a significant advancement in drug delivery, overcoming limitations of individual components.
• These nanocarriers offer versatile platforms for solubilizing hydrophobic drugs and enabling targeted delivery.
• Further research into CL and DCL formulations holds great potential for novel therapeutic strategies.